LGND Ligand Pharmaceuticals Inc - Class B

  1. Stocks
  2. Healthcare
  3. NASDAQ: LGND

Price (delayed)

$284.47

Market cap

$5.67B

P/E Ratio

28.25

Dividend/share

N/A

EPS

$10.07

Enterprise value

$5.8B

?
Relative Growth: Rel. Growth: 95
Relative Strength: Rel. Strength: 86
Relative Valuation: Rel. Valuation: 54
Relative Profitability: Rel. Profitability: 98

Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Its business model ...

Highlights
The gross profit has surged by 59% year-on-year and by 6% since the previous quarter
The revenue has surged by 55% year-on-year and by 6% since the previous quarter
The equity has grown by 17% year-on-year but it has declined by 3% since the previous quarter
The debt has soared by 150% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ligand.com
Peers: AMGN MRK BMY LLY

Key stats

What are the main financial stats of LGND

LGND stock price

How has the Ligand Pharmaceuticals stock price performed over time
Intraday
-1.65%
1 week
-0.4%
1 month
-1.48%
1 year
70.28%
YTD
50.46%
QTD
-10%

Financial performance

How have Ligand Pharmaceuticals's revenue and profit performed over time
Revenue
$290.54M
Gross profit
$277.26M
Operating income
$94.73M
Net income
$197.22M
Gross margin
95.4%
Net margin
67.9%
The gross profit has surged by 59% year-on-year and by 6% since the previous quarter
The revenue has surged by 55% year-on-year and by 6% since the previous quarter
Ligand Pharmaceuticals's net income has increased by 28% from the previous quarter
The net margin has grown by 21% from the previous quarter

Price vs fundamentals

How does LGND's price correlate with its fundamentals

Growth

What is Ligand Pharmaceuticals's growth rate over time

Valuation

What is Ligand Pharmaceuticals stock price valuation
LGND P/E details
P/E
28.25
P/B
5.89
P/S
19.64
EV/EBIT
23.74
EV/EBITDA
20.77
EV/Sales
19.95
LGND's P/E is 31% below its last 4 quarters average of 40.7
Ligand Pharmaceuticals's EPS has increased by 27% QoQ
LGND's P/B is 127% higher than its 5-year quarterly average of 2.6 and 31% higher than its last 4 quarters average of 4.5
The equity has grown by 17% year-on-year but it has declined by 3% since the previous quarter
The price to sales (P/S) is 85% higher than the 5-year quarterly average of 10.6 and 24% higher than the last 4 quarters average of 15.9
The revenue has surged by 55% year-on-year and by 6% since the previous quarter

Efficiency

How efficient is Ligand Pharmaceuticals business performance
Ligand Pharmaceuticals's ROIC has soared by 189% YoY
The company's return on equity rose by 24% QoQ
Ligand Pharmaceuticals's return on sales has increased by 21% QoQ
The ROA has increased by 5% QoQ

Dividends

What is LGND's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LGND.

Financial health

How did Ligand Pharmaceuticals financials performed over time
The company's total assets is 79% higher than its total liabilities
The company's total assets has surged by 130% YoY and by 43% QoQ
Ligand Pharmaceuticals's total liabilities has surged by 128% QoQ
The debt is 17% more than the equity
The debt to equity has soared by 160% from the previous quarter
The debt has soared by 150% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.